These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 1778087)

  • 1. Bioequivalence between two furosemide-spironolactone formulations: a pharmacokinetic and pharmacodynamic approach.
    Schütz W; Freissmuth M; Tuisl E; Blöchl-Daum B; Eichler HG; Loew D
    Curr Med Res Opin; 1991; 12(7):450-8. PubMed ID: 1778087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation on the bioequivalence of 2 oral preparations containing spironolactone and furosemide.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V
    Int J Clin Pharmacol Ther; 1998 Apr; 36(4):231-8. PubMed ID: 9587051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of metabolites--a new approach to bioequivalence studies of spironolactone formulations.
    Vergin H; Mahr G; Metz R; Eichinger A; Nitsche V; Martens H
    Int J Clin Pharmacol Ther; 1997 Aug; 35(8):334-40. PubMed ID: 9266289
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence assessment of two formulations of spironolactone in Chinese healthy male volunteers.
    Xu FG; Zhang ZJ; Dong HJ; Tian Y; Liu Y; Chen Y
    Arzneimittelforschung; 2008; 58(3):117-21. PubMed ID: 18488807
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of HPTLC and green HPLC methods for determination of furosemide, spironolactone and canrenone, in pure forms, tablets and spiked human plasma.
    Naguib IA; Abdelaleem EA; Emam AA; Ali NW; Abdallah FF
    Biomed Chromatogr; 2018 Oct; 32(10):e4304. PubMed ID: 29855049
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vivo pharmacokinetic-pharmacodynamic relationship and in vitro equivalence of two oral furosemide tablet formulations.
    Cuadrado A; Rodríguez Gascón A; Hernández RM; Castilla AM; de la Maza A; Yánez C; López de Ocáriz A; Solinís MA; Pedraz JL
    Arzneimittelforschung; 2003; 53(5):321-9. PubMed ID: 12854359
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic properties and bioequivalence of spironolactone tablets in fasting and fed healthy Chinese male subjects.
    Li ZH; Deng Y; Cai HL; Guo ZH; Hou ZY; Wu G; Yan M; Zhang BK
    Int J Clin Pharmacol Ther; 2016 Jun; 54(6):455-61. PubMed ID: 27049056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative bioavailability of two furosemide formulations in humans.
    Martin BK; Uihlein M; Ings RM; Stevens LA; McEwen J
    J Pharm Sci; 1984 Apr; 73(4):437-41. PubMed ID: 6726624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative study of pharmacokinetics and effects on urinary secretion of electrolytes of furosemide and furosemide-amiloride in healthy subjects].
    Kantelip JP; Aiache JM; Beyssac E; Abella ML
    Therapie; 1991; 46(6):475-9. PubMed ID: 1819153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analytical issues in HPLC/MS/MS simultaneous assay of furosemide, spironolactone and canrenone in human plasma samples.
    Sora DI; Udrescu S; Albu F; David V; Medvedovici A
    J Pharm Biomed Anal; 2010 Sep; 52(5):734-40. PubMed ID: 20307949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence evaluation of two brands of furosemide 40 mg tablets (Salurin and Lasix) in healthy human volunteers.
    Najib N; Idkaidek N; Beshtawi M; Bader M; Admour I; Alam SM; Zaman Q; Dham R
    Biopharm Drug Dispos; 2003 Sep; 24(6):245-9. PubMed ID: 12973821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of bioequivalence of two furosemide preparations; the effect of high doses of furosemide on some pharmacokinetic parameters.
    Wolf-Coporda A; Lovrić Z; Huić M; Francetić I; Vrhovac B; Plavsić F; Skreblin M
    Int J Clin Pharmacol Res; 1996; 16(4-5):83-8. PubMed ID: 9172005
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic and pharmacokinetic study of a slow-release formulation of furosemide in man.
    Ebihara A; Tawara K; Oka T
    Arzneimittelforschung; 1983; 33(1):163-6. PubMed ID: 6681970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical investigations on the pharmacology of azosemide (SK-110) in comparison with furosemide in healthy volunteers.
    Kuzuya F; Sugino N; Yoshizumi K; Goto U; Oshima K
    Int J Clin Pharmacol Ther Toxicol; 1984 Jun; 22(6):291-9. PubMed ID: 6746152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacodynamic assessment of diuretic efficacy and braking in a furosemide continuous infusion model.
    Adin D; Atkins C; Papich MG
    J Vet Cardiol; 2018 Apr; 20(2):92-101. PubMed ID: 29483040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.
    Levine D; Ramsay L; Auty R; Branch R; Tidd M
    Eur J Clin Pharmacol; 1976 Mar; 09(5-6):381-6. PubMed ID: 786663
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Electrolyte excretion following administration of various diuretics in healthy females].
    Matzkies F; Webs B
    Fortschr Med; 1984 Feb; 102(6):133-7. PubMed ID: 6706271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacokinetics in healthy subjects of althiazide and spironolactone in a fixed combination for 2 doses].
    Doignon JL; Grognet JM; Thébault JJ; Caplain M; Capron MH; Pelletier B; Wehrlen M; Istin M
    Therapie; 1990; 45(6):475-81. PubMed ID: 2080486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetic and pharmacodynamic interaction of single oral doses of valsartan and furosemide.
    Bindschedler M; Degen P; Flesch G; de Gasparo M; Preiswerk G
    Eur J Clin Pharmacol; 1997; 52(5):371-8. PubMed ID: 9272406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bioavailability/bioequivalence and pharmacokinetic study of two oral doses of torasemide (5 and 10 mg): prolonged-release versus the conventional formulation.
    Barbanoj MJ; Ballester MR; Antonijoan RM; Puntes M; Gropper S; Santos B; Albet C; Guglietta A
    Clin Exp Pharmacol Physiol; 2009 May; 36(5-6):469-77. PubMed ID: 19673928
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.